Physician profile
David J Woltmann
NPI 1548283567
$1,434.06
in general payments reported to CMS, 2019-2025
22 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $180 · 2021: $138 · 2022: $146 · 2023: $156 · 2024: $224 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699 · Education: $47.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.17 |
| Education | $47.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $256.62 | 2019-2025 | Krystexxa, Repatha |
| Mallinckrodt Hospital Products INC. | $155.55 | 2020-2024 | Acthar |
| Horizon Therapeutics Plc | $151.54 | 2021-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $129.16 | 2019-2025 | Voyxact, Jynarque |
| Calliditas Therapeutics US INC. | $115.72 | 2024-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $107.10 | 2019-2021 | |
| Ardelyx, INC. | $69.38 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $55.40 | 2020-2023 | Veltassa, Korsuva |
| Daiichi Sankyo INC. | $49.52 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $45.88 | 2025 | |
| Fresenius USA Marketing, INC. | $43.23 | 2023 | Korsuva, Velphoro |
| Alexion Pharmaceuticals, INC. | $40.02 | 2019-2022 | |
| Akebia Therapeutics INC | $34.54 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.16 | 2025 | |
| Nxstage Medical, INC. | $33.63 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $32.02 | 2023 | Rayaldee |
| Ani Pharmaceuticals, INC. | $23.51 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.72 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2025 | Gattex |
| Amag Pharmaceuticals, INC. | $13.00 | 2019 | |
| Genzyme Corporation | $11.04 | 2019 | |
| Travere Therapeutics, INC. | $1.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Woltmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.